Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsModeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro dataComparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.The Mycobacterium tuberculosis cytochrome P450 system.Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.Metabolism considerations for kinase inhibitors in cancer treatmentMetabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.Gefitinib for the treatment of non-small-cell lung cancer.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Clinically-relevant anticancer-antidepressant drug interactions.Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Drug interactions with phytotherapeutics in oncology.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteersPharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Alterations of gefitinib pharmacokinetics by Co-administration of herbal medications in rats.Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
P2860
Q24631021-00911024-7364-44A8-84C7-391C5AFECD2BQ28533793-FF64714E-A8AC-4EF0-B49E-E4F17BE4B163Q33574627-19E4C11B-091F-4170-BEB2-DBF56277A279Q33609979-B14E64C6-E59F-43AD-8AB7-B510B727491DQ33615471-47108E30-B6AC-4203-89BA-FA3652290B05Q34085125-1E62319C-EB8F-4F70-9503-77589A5ABCD1Q34134390-ADEC3BB2-CF8A-4584-A3C1-611F4349B8C0Q35023711-B157D722-9F75-4504-AB96-50626089FA39Q37334707-C7546E4A-A1D7-4B14-83FB-5017CBB03014Q37738913-8FDF5234-2DDD-4154-A431-A0663158995AQ37873453-4F2F98B9-EC3D-4992-983D-14BAE5D17501Q37970709-00FF0ED8-A994-4626-9472-973F69231962Q37981002-BCA35A5C-2E7A-4CFE-9D25-25456B0B9C04Q38099040-BE519D21-5DE7-47F4-A72F-102D4603BD2FQ38175476-F1EAAC4F-0A90-40FB-B5AA-97727B4D5FF7Q39031326-D3121DA5-4D40-4997-88EE-997C641DA4C5Q40513457-E3760F78-076C-4B09-9D88-EBDF3D6A3AC0Q41008169-860554C7-3431-4866-866A-85AFF554F26FQ41099660-0BFF8C23-7AA7-4824-9900-2E2509BEAC29Q42106492-4A2E0FED-F031-4F60-BFA7-6364440C4780Q43237082-32D72A1C-7AC9-416D-A734-CDD6E89564E8Q45910301-18AA5CFC-F576-4053-A23B-B63491F5141BQ45939780-EC68223F-0213-4BC4-88D4-398651A867FBQ47387077-A79067F8-F46E-41D7-B713-42CA5A367E80Q47745480-DBBEE909-7306-41DD-B505-25DFD1EFAF7CQ47885966-55C10212-9482-410D-BBF6-E3DC51D4B42FQ49582579-DE71A01F-9E01-44EA-9264-329D91041EE4Q50041679-3D877287-1710-47BD-A893-A93E27103D43Q53109204-8AE12721-8694-4B5B-8940-24A981C6F809Q53519220-99D4929A-F270-44C4-8D78-DDF140FC19DFQ55030214-90B9CC0C-352D-45EC-9B21-FC2B07B2A45F
P2860
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@ast
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@en
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@nl
type
label
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@ast
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@en
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@nl
prefLabel
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@ast
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@en
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@nl
P2093
P1476
Pharmacokinetic drug interacti ...... , itraconazole and metoprolol.
@en
P2093
Alison Laight
David McKillop
Helen C Swaisland
Joanna Leadbetter
Malcolm Ranson
Martin J Wild
Robert P Smith
P304
P356
10.2165/00003088-200544100-00005
P577
2005-01-01T00:00:00Z
P6179
1049589328